Atopic dermatitis and asthma are chronic Th2-driven inflammatory diseases; an important role in their pathogenesis is played by IL-4 and IL-13. Dupilumab is a fully human monoclonal antibody against the α subunit of IL-4 and IL-4/IL-13 receptor complexes inhibiting both IL-4 and IL-13 pathways.1 It is indicated for the treatment of difficult-tothreat atopic dermatitis in adults and as an add-on maintenance therapy in moderate-to-severe asthma with a type 2 inflammation, characterized by eosinophilia, and/or elevated fractional exhaled nitric oxide, inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.2
Success of dupilumab as a monotherapy in an adult patient affected by severe uncontrolled asthma and atopic dermatitis / Tolino, E.; Proietti, I.; Sarni, A.; Bernardini, N.; Mambrin, A.; Balduzzi, V.; Maddalena, P.; Marchesiello, A.; Michelini, S.; Volpe, S.; Skroza, N.; Potenza, C.. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - 34:1(2021), pp. 1-2. [10.1111/dth.14596]
Success of dupilumab as a monotherapy in an adult patient affected by severe uncontrolled asthma and atopic dermatitis
Tolino E.;Proietti I.;Bernardini N.;Mambrin A.;Balduzzi V.;Maddalena P.;Marchesiello A.;Michelini S.;Volpe S.;Skroza N.;Potenza C.
Conceptualization
2021
Abstract
Atopic dermatitis and asthma are chronic Th2-driven inflammatory diseases; an important role in their pathogenesis is played by IL-4 and IL-13. Dupilumab is a fully human monoclonal antibody against the α subunit of IL-4 and IL-4/IL-13 receptor complexes inhibiting both IL-4 and IL-13 pathways.1 It is indicated for the treatment of difficult-tothreat atopic dermatitis in adults and as an add-on maintenance therapy in moderate-to-severe asthma with a type 2 inflammation, characterized by eosinophilia, and/or elevated fractional exhaled nitric oxide, inadequately controlled with high dose inhaled corticosteroids plus another medicinal product.2| File | Dimensione | Formato | |
|---|---|---|---|
|
Tolino_Success-of-dupilumab_2021i.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
757.28 kB
Formato
Adobe PDF
|
757.28 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
